|
Market Closed -
Canadian Securities Exchange
18:28:53 23/10/2026 +03
|
5-day change | 1st Jan Change | ||
| 0.0200 CAD | 0.00% |
|
0.00% | -20.00% |
| Market Cap | 147K 132K 121K 110K 205K 13.99M 209K 1.45M 578K 7.32M 551K 540K 23.19M | P/E 2024 |
1.22x | P/E 2025 | -2.21x |
|---|---|---|---|---|---|
| Enterprise Value | 208K 187K 172K 156K 291K 19.85M 296K 2.05M 820K 10.39M 782K 766K 32.9M | EV / Sales 2024 |
-
| EV / Sales 2025 | - |
| Free-Float |
67.71% | Yield 2024 * |
-
| Yield 2025 | - |
Canadian Securities ExchangeCAD
| Markets | Quality | ||
|---|---|---|---|
Canadian Securities Exchange
| NSHS.X | Delayed | |
OTC Markets
| NSHSF | Delayed | |
|
Deutsche Boerse AG
| 2CG | Delayed | |
|
Börse Stuttgart
| 2CG | Delayed |
| 6 months | -20.00% | ||
| Current year | -20.00% |
| 1 month | 0.02 |  | 0.02 |
| Current year | 0.02 | | 0.03 |
| 1 year | 0.02 | | 0.04 |
| 3 years | 0 | | 0.18 |
| 5 years | 0 | | 0.29 |
| 10 years | 0 | | 23.2 |
| Manager | Title | Age | Since |
|---|---|---|---|
Richard Kaufman
CTO | Chief Tech/Sci/R&D Officer | - | 01/01/2013 |
Bennett Liu
DFI | Director of Finance/CFO | 33 | 01/11/2017 |
Toby Lim
CEO | Chief Executive Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Michael Iverson
CHM | Chairman | 74 | 10/07/2019 |
Toby Lim
BRD | Director/Board Member | - | 17/11/2017 |
Richard Kaufman
BRD | Director/Board Member | - | 17/11/2017 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 9/17/21 A | Other | Director | 0 | 0% | ||
| 9/17/21 A | Other | Director | 0 | 0% | ||
| 9/17/21 A | Sell | Chairman | 338,956 | 6.2564% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 0.00% | 0.00% | -33.33% | +33.33% | 147K | |
| +6.63% | +5.13% | +68.86% | +145.20% | 1,224B | |
| +1.53% | +2.84% | +47.48% | +89.01% | 662B | |
| +1.68% | +1.96% | +29.16% | +109.31% | 514B | |
| +0.73% | +2.45% | +54.26% | +68.96% | 388B | |
| +3.83% | -0.62% | +69.01% | +42.32% | 361B | |
| +2.38% | +2.65% | +34.31% | +57.95% | 302B | |
| +2.26% | +0.55% | +3.92% | +28.92% | 271B | |
| +1.97% | +3.01% | +57.91% | +76.14% | 249B | |
| +4.03% | +5.36% | +39.76% | +116.14% | 205B | |
| Average | +2.11% | +2.33% | +37.13% | +76.73% | 417.68B | |
| Weighted average by Cap. | +2.26% | +3.04% | +50.45% | +96.49% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | - | - |
| Net income | 263K 236K 218K 197K 368K 25.08M 374K 2.6M 1.04M 13.12M 988K 967K 41.57M | -84.78K -75.94K -70.06K -63.4K -119K -8.07M -120K -836K -333K -4.23M -318K -311K -13.38M |
| Net Debt | 28.69K 25.7K 23.71K 21.45K 40.11K 2.73M 40.76K 283K 113K 1.43M 108K 105K 4.53M | 61.51K 55.1K 50.83K 46K 86.01K 5.86M 87.4K 606K 242K 3.07M 231K 226K 9.71M |
Employees
-
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|
- Stock Market
- Stocks
- NSHS.X Stock
Select your edition
All financial news and data tailored to specific country editions
